
Monday, April 28, 2025 10:16:53 PM
Jim Lucier at CapitalAlpha Partners advises that there is a placeholder for the House Financial Services Committee to find “savings,” but nothing specific as yet on the assumed value of a GSE release from conservatorship in a budget reconciliation. “That would properly be in the Finance title of the reconciliation tax bill that gets marked up on April 30,” he muses. “We could get a chairman's mark the day before, but I suspect that we won't see a chairman's mark until the day of.”
Members of Congress are not particularly worried about reading legislation before the vote so long as all of the numbers continue to go up. Whether the GSEs exit conservatorship is mostly a matter of indifference. Most MCs could not even explain the meaning of the term GSE. The good news of sorts is that the GSEs will indeed exit conservatorship -- if the Trump Administration uses the cash value to support a budget reconciliation.
The bad news is that the US will end up owning well-more than 95% of the equity upon release, including the crushing dilution of the private investors and also the Treasury’s own preferred position by the accumulating liquidity preference. Sorry hedge fund peeps, full dilution awaits common holders, no forgiveness. And for this reason, we think the Trump Administration will be forced to restructure the GSEs to unlock cash in the shortest period of time.
As we told a room full of very smart people yesterday, our preference for restructuring the GSEs will be for the Treasury to convert its option into common shares, then further issue new common shares to repay the liquidation preference as required by the same federal law that applied to GM, AIG and Citigroup. But unlike these commercial companies, the GSEs will never be truly free of control by the Treasury.
https://www.theinstitutionalriskanalyst.com/post/budget-reconciliation-fiscal-credibility-gse-release
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM